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occurs only in the 2 step approach, we compared engraft-
ment rates and IR between the 2 groups. All 92 patients had
good risk disease. In the 1 step vs the 2 step study, median
time to ANC > 500/ul was 19(range 15-28 days) vs 11[range
9-16 days (p¼0.000-Mann-Whitney)], and for platelets
> 20,000/ul, 29(range 18-52 days) vs 17(range 12-173 days)
respectively (ns). The signiﬁcant difference in time to ANC
recovery in the 1 step group was possibly from the exposure
of the donor PBSC’s to CY. When we accounted for the later
occurrence of day 0 in the 2 step group, the median time to
ANC recovery was still 3 days longer in the 1 step group even
though this group received a higher median CD 34 dose.
Possibly due to the earlier count recovery in the 2-step group,
the median CD3/4 count at day 28 was 20(range 5-50/ul) in
the 1 step group vs 54(range 11-299/ul) in the 2 step group.
By day 90, differences between the groups resolved, with a
median CD3/4 count of 157(range 29-397/ul) vs 147(range
10-814/ul) in the 1 and 2 step groups respectively. Median
CD3/8 count at day 28 was 40 (range 3-157/ul) vs 57 (range
4-2682/ul) and at day 90 was 239(range 12-1439/ul) vs
204(range 2-2379/ul) in the 1 and 2 step groups respectively.
The percentages of patients on steroids for GVHD at day 28
(13% in the 1 step group vs 31%) and 90 (18% vs 33%) was not
signiﬁcantly different between the two groups (p¼0.215 and
0.413 respectively, Pearson Chi Square). Themedian length of
stay (LOS) was 41(range 15-99 days) vs 32(range 15-156
days) in the 1 and 2 step groups respectively. The 2 step
approach to HSCT allows for the administration of a ﬁxed
dose of T cells from which to optimize outcomes and cir-
cumvents exposure of donor cells to the effects of CY. Our
experience with a 1 step approach suggests later ANC re-
covery and possibly initial T cell recovery versus the 2 step
approach. There may be a slightly longer LOS in the 1 step
group possibly from longer time to count recovery. Formal
analyses of the differences between the two approaches will
be performed when more patients are treated at our insti-
tution with the 1 step approach.Table 1
Patient characteristics comparing cases and controls
Cases (n¼5) Controls (n¼15) P value
Age (Median with range) 43 (21-68) 47 (27-71) 0.646
Male gender 5 (100%) 13 (86.7%) 1.000
Type of transplant
Allogeneic e Related,
Unmatched
0 (0%) 3 (20%) 0.539
Allogeneic e Unrelated,
Matched
3 (60%) 2 (13.3%) 0.073
Allogeneic e Unrelated,
Unmatched
1 (20%) 7 (46.7%) 0.603
Autologous 1 (20%) 3 (20%) 1.000
Immunosuppressive therapy on day + 14
Tacrolimus 4 (80%) 11 (73.3%) 1.000
Corticosteroids 0 (0%) 1 (6.7%) 1.000
Mycophenolate 1 (20%) 2 (13.3%) 1.000
GvHD 3 (60%) 2 (13.3%) 0.073
WBC 4.1 (0.2-9) 4.7 (0.8-9.2) 0.668
ANC 3.0 (0.7-5.3) 3.2 (0.1-9.3) 0.882
Hemoglobin 8.7 (6.8-10) 10.7(7.2-14) 0.066
Platelets 70 (7-165) 120 (35-236) 0.147
Cr 1.25 (0.83-1.97) 0.84 (0.38-1.29) 0.081
Alk Phos 85 (36-138) 69 (50-95) 0.243
Total bilirubin 1.2 (0.6-2) 0.6 (0.3-0.9 0.003
ALT 71(10-151) 29 (8-71) 0.026
Albumin 2.6(2.2-3.1) 3.7 (2.7-4.2) < 0.001397
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Introduction: HHV6 (Human Herpes Virus 6) reactivation
occurs in approximately one-half of patients following allo-
geneic hematopoietic stem cell transplant (HSCT). The target
tissues of HHV6 and the extent to which HHV6 causes dis-
ease in those with viremia is not resolved.
Methods: Biopsies or body ﬂuid sampling are routinely
performed at our center to determine the cause of otherwise
unexplained end-organ disease. We describe 14 pediatric
HSCT patients who were found with HHV6 PCR end-organ
tissue positivity on these studies. Of these 14 patients, 13 had
received myeloablative conditioning, 12 had received an
unrelated donor graft, 10 had underlying malignant disease,
9 patients had acute GVHD, and 3 were diagnosed with
chronic GVHD.
Results: Robust statistical partitioning identiﬁed two distinct
subgroups within this population based on the highest HHV6
viral load in blood. In 10 of the 14 patients, a peak blood viralload (>28,000 copies/mL) occurred developed while the
other 4 patients had peak blood viral loads<2000 copies/ml.
All patients received antiviral treatment to treat their
viremia. At the time of biopsy and/or ﬂuid sampling, only 1
patient out of 14 had a blood viral load >28,000 copies/mL
and the remainder had very low (<1500 copies/ml) or un-
detectable HHV6 virus in the blood despite having detectable
virus in their tissues. In total, 8/14 patients biopsied patients
who had tissue/body ﬂuid viral positivity did not have con-
current detectable virus in blood, in 5/14, the blood viral load
was <1500 copies/ml, while only in one patient who had
encephalitis there was a high copy number of 344,488
copies/ml detected in blood at the time of detection of the
virus in the cerebrospinal ﬂuid (CSF).
HHV6was found in CSF (3 patients), BAL ﬂuid (3 patients),
GI tract (5 patients), bone marrow (5 patients), pericardial
ﬂuid (3 patients), liver (1 patient), and gallbladder (2 pa-
tients). Statistical analysis showed no difference between the
two subgroups with respect to age, gender, stem cell graft,
stem cell donor, HLA compatibility between the donor and
the recipient, acute/chronic graft-versus-host disease, or
survival. Of note, 4 out of 14 patients had co-existent CMV
viremia. There was a decreasing linear trend (Cochran-
Armitage P¼0.015) in the association (Fisher’s exact
P¼0.041) between CMV viremia and HHV6 viral load group:
3 patients with CMV viremia were in the low HHV 6 viral
load group versus 1 patient in the high group. Five of the
fourteen patients died (one of whom relapsed), suggesting a
high non-relapse mortality rate (28%) in this population.
Conclusion: End-organ disease/dysfunction with HHV6
positivity can persist despite a decrease in peripheral viral
load after antiviral treatment. Further studies will elucidate
whether prolonged or intensive antiviral treatment is war-
ranted in such cases.
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Table 2
Outcomes of HSCT patients with adenovirus infectious disease and matched
controls
Cases (n¼5) Controls (n¼15) P-value
Death or hospice discharge 2 (40%) 0 (0%) 0.053
Relapse of malignancy 4 (80%) 3 (20%) 0.031
Recurrent hospitalization 1 (20%) 3 (20%) 1.000
Infection 1 (20%) 1 (6.7%) 0.447
GVHD 0 (0%) 2(13.3%) 1.000
Other infections 4 (80%) 9 (60%) 1.000
Pneumonia 1 (20%) 2(13.3%) 1.000
Urinary tract infection 2 (40%) 0 (0%) 0.053
C. difﬁcile 0 (0%) 2(13.3%) 1.000
Other respiratory virus 0 (0%) 0 (0%) 1.000
Bloodstream infection 2 (40%) 4 (26.7%) 1.000
BK viruria 4 (80%) 1 (6.7%) 0.032
CMV viremia 1 (20%) 5 (33.3%) 1.000
EBV viremia 1 (20%) 0 (0%) 0.250
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Purpose: Recently, the expanded availability of adenovirus
PCR assays has allowed the detection of quantitative
adenovirus viremia in patients. Few studies have examined
the impact of adenovirus viremia in blood or marrow
transplant patients and the value of using PCR to detect
adenovirus in the blood of these patients.Table 3
Treatment and timing of therapy in patients with adenoviral infection
Patient No. Attempt
to treat
Reduction of
immunosuppression
Cidofovir Days (dose)
1 Yes Yes Intravenous 75 (1mg/kg
2 Yes N/A Intravenous 85 (5mg/kg
3 No No N/A
4 Yes Yes Intravenous 92 (5mg/kg
5 Yes No Intravenous 24 (3mg/kg
70 (6.5mg/kMethods: This is a case-control study of all adult blood or
marrow transplant recipients diagnosed with adenovirus
viremia via blood PCR assay at a single university based
cancer center from 4/1/2010 to 5/1/2013. Three controls
matched for malignancy, and type and year of transplant
were chosen per case. Epidemiologic and clinical data were
collected from chart review of identiﬁed patients.
Results: During the study period, 805 patients underwent
blood or marrow transplantation; 61% of which were autol-
ogous. Five (0.6%) patients developed adenovirus viremia
post-transplant at a median of 68 days (range 17-79 days)
post-transplant. Table 1 shows the demographic comparison
between cases and controls. Cases had signiﬁcantly higher
total bilirubin (1.2 vs 0.6 mg/dL; p¼0.003) and ALT levels (71
vs 29 U/L; p¼0.03) and lower albumin (2.6 vs 3.7 g/dL;
p<0.001). Adenovirus viremia was associated with fever in
80% of patients, hematuria/cystitis in 60%, and sore throat in
40%. Table 2 reports outcomes of cases and controls. Two
(40%) of the case patients died; one of sepsis and one of
failure to thrive. Cases were more likely to have relapse of
theirmalignancy (80% vs 20%; p¼0.03) and BK viruria (80% vs
7%; p¼0.03). Table 3 describes the treatment courses of the
cases.
Conclusions: Adenovirus viremia in blood or marrow
transplant recipients is rare. The illness may correlate with
relapse of malignancy and higher mortality, but larger
studies need to be performed to investigate this ﬁnding
further. Adenovirus viremia also appears to occur more
frequently in patients with BK viruria, suggesting it may also
be a disease of over immunosuppression.Comments
), 77 (5mg/kg), 84 (5mg/kg)
)
Symptoms resolved
), 99 (5mg/kg), 106 (5mg/kg) Discharged to hospice while still viremic
), 57 (1mg/kg), 63 (4mg/kg),
g), 77 (6.5mg/kg)
Discharged to hospice while still viremic
